Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.18    -0.005 (-2.70%)
Bid:
0.17
Ask:
0.19
Spread: 0.02 (11.765%)
Market Cap: £1.34m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Convertible Loan Note Offer

18 Jul 2006 15:48

Azure Holdings PLC18 July 2006 Azure Holdings plc (the "Company") Convertible Loan Note Offer The Company announces that it has today issued a letter to holders of ordinaryshares of 1p each in the Company ("Ordinary Shares"), on the share register ofthe Company on 17 July 2006, offering them the opportunity to participate in thesubscription of up to £1,200,000 nominal unsecured convertible loan stock 2008("Loan Stock"). The Loan Stock is being offered following discussions regarding a proposedacquisition by the Company ("Acquisition"). The proposed target for theAcquisition is ValiRX Limited ("ValiRX"), a biopharmaceutical developmentcompany. Discussions with ValiRX are progressing and the directors of theCompany hope to complete a reverse takeover under the AIM rules before 30September 2006. The principal terms of the Loan Stock are as follows: 1 Unless previously converted or repaid, the Loan Stock isrepayable 24 months from the date of the Loan Stock instrument under which it iscreated (the "Instrument") or at any time after 31 October 2006 at the Company'soption. 2 In partial consideration for the Loan Stock holderssubscribing for Loan Stock, a premium ("Premium") of £2 for each £1 nominal ofLoan Stock is payable, unless previously converted or paid, 24 months from thedate of the Instrument, or at any time after 31 October 2006 at the Company'soption. 3 Interest is payable from 1 November 2006 on the amount ofthe Loan Stock at the rate of two per cent. over the base rate of the Bank ofScotland plc from time to time. Interest is payable twice yearly. The firstinterest period will run from 1 November 2006 to 31 March 2007. 4 The conversion of Loan Stock ("Conversion") into OrdinaryShares is conditional upon approval by shareholders of resolutions to allotshares and disapply pre-emption rights; and if appropriate, the approval by avote of independent shareholders taken on a poll of any waiver granted by thePanel on Takeovers and Mergers of any obligation under rule 9 of the City Codeon Takeovers and Mergers which may arise from such Conversion (together the "Conversion Event") 5 Immediately prior to the Conversion Event, the Loan Stockis deemed repayable and the Premium is deemed payable. 6 On the Conversion Event, the Loan Stock and the Premiumwhich has not been repaid or paid as the case may be, will be converted intoOrdinary Shares in the capital of the Company at the rate of 100 Ordinary Sharesof the Company for each £1 otherwise due for repayment or payment. 7 So far as it is lawfully able to do so, the Company willnotify the Loan Stock holders at least 10 days in advance of the likelyoccurrence of the Conversion Event. 8 The Loan Stock is transferable in multiples of £10,000. 9 The Company is obliged to repay the Loan Stock and pay thePremium on the occurrence of certain events, including certain insolvencyevents. 10 Decisions relating to the Loan Stock are to be taken by a writtenresolution of the holders of at least two thirds in nominal value of theoutstanding Loan Stock. Applications for the Loan Stock may only be made for a minimum of £1,000 nominaland in multiples of £1,000. Applications for the Loan Stock are to be receivedby the Company at One Great Cumberland Place, London W1H 7AL by 3.00pm on 31July 2006. A copy of the letter despatched to shareholders and the Instrument are availablefor inspection, on request, at Halliwells LLP, 1 Threadneedle Street, LondonEC2R 8AW during normal business hours on any weekdays, Saturdays, Sundays andpublic holidays excluded, for one month from today. For further information, please contact: Barry Gold, Azure Holdings plcTel: 07768 948 928 David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Oct 20147:00 amRNSApproved Clinical Trial Update
8th Oct 20144:12 pmRNSEarly Completion of Equity Swap Agreement
8th Oct 20144:08 pmRNSHolding(s) in Company
2nd Sep 20147:00 amRNSValiSeek Development Update
28th Aug 201411:33 amRNSHolding(s) in Company
19th Aug 20147:00 amRNSHalf Yearly Report
5th Aug 201412:05 pmRNSHolding(s) in Company
4th Aug 20147:00 amRNSNotice of Acceptance of CTA Request
1st Jul 201411:35 amRNSHolding(s) in Company
24th Jun 20147:00 amRNSDirector/PDMR Shareholding
18th Jun 20149:22 amRNSNew Corporate Website & New Office Address
10th Jun 20147:00 amRNSSubmission of Clinical Trial Application re VAL201
15th May 20147:00 amRNSValiSeek Development Update
1st May 20147:00 amRNSNew Japanese Patent Grant
23rd Apr 20144:29 pmRNSResult of AGM
17th Apr 20145:51 pmRNSHolding(s) in Company
8th Apr 20147:00 amRNSValiSeek Joint Venture
1st Apr 20147:00 amRNSVAL201 Update
31st Mar 20144:45 pmRNSNotice of AGM
31st Mar 20144:09 pmRNSHolding(s) in Company
28th Mar 20147:01 amRNSPosting of R&As and Notice of AGM
19th Mar 20147:00 amRNSFinal Results
20th Feb 20147:00 amRNSNew European Patent Grant
31st Jan 201412:45 pmRNSSale of shares in VolitionRx
22nd Jan 20143:00 pmRNSGrant of Options
16th Jan 20147:00 amRNSIssue of Equity
27th Dec 20137:00 amRNSFundraising and Equity Swap
5th Dec 20137:00 amRNSNew Australian Patent Grant
28th Nov 20137:00 amRNSUpdate re Positive VAL201 & Biomarker Unit Studies
15th Nov 20137:00 amRNSPlacing to raise £1m
1st Nov 20137:00 amRNSChange of Broker
24th Oct 20134:25 pmRNSRe: VAL201 - Update
8th Oct 20137:00 amRNSDirectorate Changes
5th Sep 20137:00 amRNSHalf Yearly Report
15th Aug 20137:00 amRNSConsortium incl. ValiRx Awarded Eurostars Grant
31st Jul 20137:00 amRNSUpdate
25th Jun 20137:00 amRNSInvestor Presentation in Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
13th Jun 20137:00 amRNSRe: VAL201 Update
6th Jun 201310:00 amRNSValiRx admitted as founder member of the SSE
25th Apr 20137:00 amRNSNew Patent Granted
22nd Apr 201311:52 amRNSResult of AGM
2nd Apr 20137:00 amRNSUpdate on Developmental and Clinical Activity
28th Mar 20137:01 amRNSFinal Results
21st Feb 20137:00 amRNSRe Commercial Development Update
23rd Jan 20137:00 amRNSAppointment of Medical Monitoring Officer
31st Dec 20127:00 amRNSTotal Voting Rights
22nd Nov 20127:00 amRNSRe: Update
19th Nov 201212:19 pmRNSResult of General Meeting
1st Nov 20121:49 pmRNSPlacing and Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.